The Keller Laboratory at cc-TDI: 12/01/2008

Tuesday, December 30, 2008

PPTI receives its first contribution for Drug Testing in Rhabdomyosarcoma

We thank our anonymous donor for a kind $500 contribution towards the Pediatric Preclinical Testing Initiative, with the specific goal of advancing new treatments for alveolar rhabdomyosarcoma.

For more information about the Pediatric Preclinical Testing Initiative and our grass-roots effort to advance research in childhood cancers, email Charles at kellerc2@uthscsa.edu .

[right: this graphic design and implemented by Charles Keller and David Rodriguez.]

Monday, December 15, 2008

Welcoming Anu!

We are excited to welcome Anuradha "Anu" Soundararajan to our research team. Anu obtained a Bachelor’s degree in Physics from the University of Madras in 2000, where she was recognized with the award for Best Outgoing Student for her college. After earning a Masters degree in medical physics from Anna University then professional experience as a Medical Physicist at the Cancer Institute in India, Anu pursued and recently completed a PhD in Medical Diagnostic Physics from the Department of Radiology at UTHSCSA. William “Bill” Phillips and Beth Goins were mentors to Anu, whose doctoral thesis project related to Chemo-Radionuclide Therapy with 186-Re labeled Liposomal Doxorubicin in combination with Radiofrequency Ablation for Effective Treatment of Head and Neck Cancer. Anu brings specific new strength to our research program in the area of Molecular Imaging. Her long term career goals include applied academic research for cancer using genetically engineered mouse models, imaging, and image-guided therapies. Welcome, Anu!

Tuesday, December 9, 2008

Our Sincerest Thanks to Mei

We sincerely thank consultant Mei Zhang for our tutorial on advanced mouse ultrasound imaging this past week. Mei is a clinical and preclinical ultrasonographer with a special gift as a teacher. Her thoughtful on site training makes it possible for us to better determine the response of childhood rhabdomyosarcomas to novel targeted therapies. We are so grateful to you, Mei. Charles, Aoife and the Keller Lab Team.

Monday, December 8, 2008

CIBC Workshop

Charles and Suresh attended a workshop for the Center for Integrative Biomedical Computing at the Scientific Computing and Imaging Institute of the University of Utah this past week. Our lab is a Tier 1 collaborator for the NIH/NCRR grant that supports the CIBC (P41RR012553). We are excited about the tools made available by CIBC that enhance our study of childhood cancers, particularly Seg3D and Jens Krüger's new ImageVis3D. Staying an extra day, Suresh also mastered snowboarding... a great trip altogether!

You Can Participate in our Novel Therapeutics Studies !

One would like to think that tangibly better treatments for rhabdomyosarcoma, medulloblastoma and other childhood cancers can be found in a matter of years, instead of tens of years. Finding new treatments starts with research, perhaps even a new research approach to identifying effective new treatments. The Children's Cancer Therapy Development Institute focuses on finding molecules in childhood cancers that can be directly turned off or on by drugs so that the tumor stops growing. Behind our novel approach is the use of genetically-engineered mice. Our Pediatric Preclinical Testing Initiative uses mice modified from before birth so that at a certain age, and in a certain tissue, the same mutations found in a child’s cancer are activated in the mouse. These special mouse models of childhood cancer can be used to test a treatment to see whether the tumor growth and spread (metastasis) can be reversed. The specific aspect of these mice having normal immune systems is a real plus, too, because white blood cells play an important role in how tumors evolve and respond to therapy.

Our program is designed around community participation. Through the Children's Cancer Therapy Development Institute, you can contribute directly to this grass-roots initiative. Donations through small gifts or grants will assist in studying compounds that may be effective in treating such childhood cancers as alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, or medulloblastoma (the alveolar rhabdomyosarcoma model was featured by Dr. Keller's long time collaborator and former mentor, 2007 Nobel laureate Mario Capecchi, in his Nobel Prize lecture {see 16 minutes onward}.)

For additional information regarding supporting this program please contact Charles Keller at charles@cc-tdi.org. Results obtained through these studies will be shared with the National Cancer Institute’s Cancer Therapy Evaluation Program, as well as the Children’s Oncology Group, which designs clinical trials for childhood cancer.